Symbiotec Pharmalab Limited Q2 Revenue Rises 43% to ₹280 Crore

Symbiotec Pharmalab Limited reported consolidated revenue of ₹280 crore for Q2 FY27, up 43% year-on-year, with EBITDA rising 82% to ₹92 crore and profit after tax increasing 169% to ₹52 crore. The results point to a materially stronger September-quarter performance alongside progress in complex injectables and CDMO services.

What did Symbiotec Pharmalab Limited report for Q2 FY27?

Symbiotec Pharmalab Limited reported consolidated revenue of ₹280 crore in Q2 FY27, compared with the corresponding quarter a year earlier, representing 43% growth. Reported EBITDA rose 82% year-on-year to ₹92 crore, while the EBITDA margin was 32.7%.

Profit after tax for the quarter stood at ₹52 crore, a year-on-year increase of 169%. The company’s Q2 performance followed a weaker reported Q1 FY27 profit number of ₹14.1 crore, although Q1 revenue was ₹218.2 crore.

For the first half of FY27, Symbiotec reported revenue of ₹498 crore, up 25% year-on-year. H1 EBITDA was ₹136 crore and H1 profit after tax was ₹66 crore, up 34% from the comparable period.

How did the Q2 FY27 results follow the first quarter?

Symbiotec’s H1 FY27 revenue of ₹498 crore includes ₹218.2 crore of revenue reported for Q1 FY27 and ₹280 crore for Q2 FY27. This indicates that the September quarter contributed the larger share of first-half revenue.

The profitability pattern was also stronger in Q2. Q1 FY27 EBITDA was reported at ₹45.2 crore, with an operating margin of about 20.7%, whereas Q2 EBITDA was ₹92 crore and the reported EBITDA margin was 32.7%.

Q1 FY27 profit after tax was ₹14.1 crore, compared with ₹52 crore in Q2 FY27. The first-half PAT of ₹66 crore reflects these two reported quarterly figures. The supplied financial update does not specify the individual cost, pricing, product-mix, or other factors behind the quarter-on-quarter movement.

What business developments supported Symbiotec’s update?

Symbiotec said its APIs business recorded sales growth of 11% during H1 FY27. The company also stated that it completed four major regulatory audits, including EUGMP and USFDA audits.

In complex injectables, the company signed a licensing agreement for the distribution of two DCV products in the United States. It recognised part revenue of ₹53 crore from this arrangement. The update does not provide the total contract value, distribution timeline, or the split of this revenue between periods.

Its CDMO services update included progress in an Industrial Biotech division. Symbiotec referred to a 10-year take-or-pay agreement and continuing work on a European partnership. These developments show the company is building business lines beyond its established API operations, though the supplied information does not quantify expected earnings from the CDMO initiatives.

What is Symbiotec Pharmalab Limited’s planned capital expenditure?

Symbiotec announced plans to invest more than ₹1,000 crore in capital expenditure for new businesses. The company said revenue from these businesses is expected to commence over the next 6-12 months.

The planned investment is material compared with the ₹498 crore revenue reported in H1 FY27. It places execution, commissioning timelines, customer conversion and funding arrangements at the centre of the company’s next operating phase. The update does not disclose the detailed allocation of the capex, its financing structure, or project-wise revenue targets.

The new-business investment is relevant because it sits alongside the company’s API, complex injectables and CDMO strategy. Regulatory audit completion, the US distribution licensing arrangement and long-term CDMO agreements are operational milestones that may support this expansion, but the company has not provided a consolidated financial forecast for these initiatives.

How do the results matter for investors and industry operations?

The Q2 figures show higher revenue and a marked improvement in reported EBITDA and PAT growth compared with the year-earlier quarter. The EBITDA margin of 32.7% is also above the approximately 20.7% operating margin reported for Q1 FY27, based on the information provided.

For investors, the key reported data are the 43% Q2 revenue growth, the 82% rise in EBITDA and the 169% increase in PAT. No share-price movement, valuation data, dividend decision or management earnings guidance was provided in the source material, so the results alone do not establish a market reaction.

For customers and industry participants, the four completed regulatory audits and the US distribution agreement are relevant operational updates. Compliance with EUGMP and USFDA audit requirements is important for pharmaceutical manufacturing and export activity, while the CDMO and industrial biotechnology initiatives broaden the areas in which the company is seeking commercial scale.

Conclusion

Symbiotec Pharmalab Limited reported a stronger Q2 FY27, with ₹280 crore of consolidated revenue, ₹92 crore of EBITDA and ₹52 crore of PAT. The half-year numbers also show 25% revenue growth, while updates in APIs, complex injectables and CDMO services add context to the financial performance.

The next disclosed event is the earnings conference call scheduled for November 6, 2026, at 9:30 AM IST, hosted by Avendus Spark to discuss Q2 FY27 and H1 FY27 performance and business updates. Investors will also watch the commencement of revenue from the planned new businesses over the stated 6-12 month period and progress on the more than ₹1,000 crore capex plan.